Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hilbert

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Journal of Medicinal Chemistry|January 17, 2025
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerBenjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, et al.
Journal of the American Academy of Dermatology|June 19, 1998
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenailP Rich, R K Scher, D Breneman, et al.
Environmental Health Perspectives|May 23, 2024
Child and Adolescent Manganese Biomarkers and Adolescent Postural Balance in Marietta CARES Cohort ParticipantsDanielle E McBride, Amit Bhattacharya, Heidi Sucharew, et al.
ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.
Cell Reports|December 16, 2017
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its IdiotopeYuval Avnir, Kristina L Prachanronarong, Zhen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsRaymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.
Journal of the American Academy of Dermatology|June 19, 1998
Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernailR C Savin, L Drake, D Babel, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Journal of Medicinal Chemistry|January 17, 2025
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung CancerBenjamin C Milgram, Deanna R Borrelli, Natasja Brooijmans, et al.
Journal of the American Academy of Dermatology|June 19, 1998
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenailP Rich, R K Scher, D Breneman, et al.
Environmental Health Perspectives|May 23, 2024
Child and Adolescent Manganese Biomarkers and Adolescent Postural Balance in Marietta CARES Cohort ParticipantsDanielle E McBride, Amit Bhattacharya, Heidi Sucharew, et al.
ESMO Open|August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumorsE Borazanci, A M Schram, E Garralda, et al.
Cell Reports|December 16, 2017
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its IdiotopeYuval Avnir, Kristina L Prachanronarong, Zhen Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsRaymond A Pagliarini, Jack A Henderson, Benjamin C Milgram, et al.
Journal of the American Academy of Dermatology|June 19, 1998
Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernailR C Savin, L Drake, D Babel, et al.
Pageof 11